These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20006217)

  • 1. First report of hypoglycemia secondary to dandelion (Taraxacum officinale) ingestion.
    Goksu E; Eken C; Karadeniz O; Kucukyilmaz O
    Am J Emerg Med; 2010 Jan; 28(1):111.e1-2. PubMed ID: 20006217
    [No Abstract]   [Full Text] [Related]  

  • 2. Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.
    Dailey G; Strange P
    Am J Manag Care; 2008 Jan; 14(1):25-30. PubMed ID: 18197742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
    J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of an intermediate action insulin in diabetics non-respondents to oral treatment].
    Díaz C J; Moneada V S; Orriols W M; Durruty A P
    Rev Med Chil; 2007 Oct; 135(10):1358-60. PubMed ID: 18180847
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
    De Mattia G; Laurenti O; Moretti A
    Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin.
    Davis MD; Beck RW; Home PD; Sandow J; Ferris FL
    Exp Clin Endocrinol Diabetes; 2007 Apr; 115(4):240-3. PubMed ID: 17479440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Long-acting insulin analogs: progressing slowly].
    Holleman F; Hoekstra JB
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1668-9. PubMed ID: 15453117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lantus is superior in BOT (basic oral therapy) to standard mixed insulin].
    Krankenpfl J; 2004; 42(5-6):172. PubMed ID: 15527234
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
    Monami M; Marchionni N; Mannucci E
    Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New insulin with uniform action. Hazards of blood sugar variations minimized].
    MMW Fortschr Med; 2003 Oct; 145(40):55. PubMed ID: 14603609
    [No Abstract]   [Full Text] [Related]  

  • 11. [Night-time hypoglycemia in patients with type 2 diabetes].
    Stiefelhagen P
    MMW Fortschr Med; 2009 Jun; 151(26-29):40-1. PubMed ID: 19739548
    [No Abstract]   [Full Text] [Related]  

  • 12. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experiences of patients with insulin-treated diabetes in conscript military service.
    Sane T; Rautuoja A; Mäkelä M; Westerberg J; Lehesjoki M
    Diabet Med; 2007 Jan; 24(1):87-90. PubMed ID: 17227329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin detemir: a new basal insulin analogue.
    Soran H; Younis N
    Diabetes Obes Metab; 2006 Jan; 8(1):26-30. PubMed ID: 16367879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy in type 2 diabetes: the role of repaglinide.
    Moses R
    J Assoc Physicians India; 2001 Jan; 49 Spec No():62-8. PubMed ID: 11235608
    [No Abstract]   [Full Text] [Related]  

  • 18. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
    Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Spanish experience with insulin lispro].
    Reviriego Fernández J
    An Med Interna; 1998 Jul; 15(7):384-90. PubMed ID: 9710993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
    Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.